Vladimir Bryntsalov is ready to part with his last pharmaceutical asset

The most recent financial statements for Bryntsalov A, presented in open sources, date back to 2021. And they were not encouraging. According to SPARK-Interfax, JSC (100% owned by the American Bryntsalov Pharmacrutics) closed the year with revenue of 1.7 billion rubles and a net loss of 323 million rubles (the company ended 2020 with a profit of 2.7 million rubles). All subsequent news about the company was also alarming. Since November 2024, four messages about the intention to apply to the arbitration court with an application to declare Bryntsalov A bankrupt have been published in the Unified Federal Register of Information on the Facts of Activities of Legal Entities - from Aurora LLC, Agro Azbuka LLC and two from TSK Mosenergo LLC. As of September 10, 2025, the Federal Tax Service decision to suspend operations on accounts is also in effect with respect to JSC Bryntsalov-A.

Bryntsalov's partner in the company "Hunt-Holding" (which manages the entrepreneur's real estate assets), businessman Denis Konovalenko, did not respond to Vademecum's request. However, market participants familiar with Bryntsalov's plans say that he is ready to sell the enterprise for 2 billion rubles.

According to the State Register of Medicines, JSC Bryntsalov-A has 30 valid registration certificates for drugs, including the antibiotics Ampiox (ampicillin + oxacillin), Gentamicin-Ferein (gentamicin), Ampicillin-Ferein (ampicillin), Cefalozin-Ferein (cephalosin), Erythromycin (erythromycin), the antiviral Riboxin-Ferein (inosine), the antiemetic Ceruglan (metoclopramide), the anti-inflammatory Ortofer (diclofenac), and others.

The Elektrogorsk plant first became the main, and soon the only production pharmaceutical site of Bryntsalov in 2013, when the owner decided to lease the premises and workshops of the Ferein plant on Nagatinskaya Street in Moscow to third-party tenants. In 2017, the Barkley corporation announced the closing of a deal to acquire a land plot from the Ferein pharmaceutical plant on Nagatinskaya Street in Moscow, where the corporation planned to build a residential complex. The deal was estimated at 8-10 billion rubles, and the planned project implementation period was 5 years. However, in 2019, as reported by the publication Pravo.ru, a conflict arose between the parties to the agreement, as a result of which Barkley initiated a deal to sell the company, which was a co-investor in the original project, to Hunt Holding. Currently, active construction is underway around the territory of the former Ferein, but the main building of the plant is still not included in the development perimeter.

The Ferein plant was built in 1912. In the 1990s, the enterprise (then called the Moscow Chemical-Ferrous Plant named after L.Ya. Karpov) was taken over by the family of entrepreneur Vladimir Bryntsalov. In 1997, Ferein began producing insulin under a license from the Danish Novo Nordisk, but a year later the Danes accused Ferein of violating the license agreement by transferring rights to a third party, ZAO Bryntsalov-A, and terminated the agreement.

The peak of Vladimir Bryntsalov's pharmaceutical business development came at the beginning of the 2000s. But already in 2007, the Investigative Committee of the Ministry of Internal Affairs of Russia brought charges against the heads of Bryntsalov-A for illegal entrepreneurship and illegal use of a trademark at the enterprise's production facilities. All the defendants, including Vladimir Bryntsalov's sister Tatyana, were found guilty but received suspended sentences. Vladimir Bryntsalov himself did not participate in the trial. At that time, he was permanently residing abroad. After the events of 2007, Bryntsalov A disappeared from the TOP domestic pharmaceutical manufacturers.

In 2020, after 15 years of absence from the public eye, Vladimir Bryntsalov gave an interview to Vademecum publisher Dmitry Kryazhev for the book “Tabletized Pharma” published in 2021.